• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The Covid Pandemic: Broadening the Discourse
Thailand’s COVID-19 response an example of resilience and solidarity: a UN Resident Coordinator’s BlogBy Asoka BandarageCOLOMBO, Sri Lanka, Nov 10 2020 (IPS) SARS-CoV-2, the corona virus that causes COVID-19, has been spreading exponentially across the world over the last ten or so months. As of November 6th, according to the Center for Systems Science at Johns Hopkins University, there have been 49,195,581 cases of COVID-19, including 1,241,031 deaths. More than a third of the global population has been placed on lockdown. The global economy is experiencing the deepest global recession since World War 2 and massive n...
Source: IPS Inter Press Service - Health - November 10, 2020 Category: International Medicine & Public Health Authors: Asoka Bandarage Tags: Featured Global Headlines Health Human Rights Humanitarian Emergencies Peace TerraViva United Nations Source Type: news

NIH study aims to identify promising COVID-19 treatments for larger clinical trials
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases today launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and merit advancement into larger clinical trials. The ACTIV-5 Big Effects Trial, which will enroll adult volunteers hospitalized with COVID-19 at as many as 40 U.S sites, is being conducted in collaboration with the NIH's public-private partnership Accelerating COVID-19 Therapeutic Innovations and Vaccines (ACTIV) program.
Source: EurekAlert! - Medicine and Health - October 13, 2020 Category: International Medicine & Public Health Source Type: news

Mount Sinai and AllerGenis, LLC announce partnership to bring novel, precision diagnostics to food allergy patients
(The Mount Sinai Hospital / Mount Sinai School of Medicine) AllerGenis, LLC, a data-driven diagnostic company, announced a partnership agreement with Mount Sinai Health System to develop and commercialize technology for improved food allergy detection and patient management. The diagnostic technology will provide information to both patients and clinicians.
Source: EurekAlert! - Social and Behavioral Science - November 7, 2018 Category: International Medicine & Public Health Source Type: news

NIAID and Children's National partner to advance pediatric clinical research
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and Children's National Health System, a pediatric academic medical center in Washington, D.C., have launched a clinical research partnership devoted to treating and preventing allergic, immunologic and infectious diseases in children. An inaugural symposium will take place at Children's National on Sept. 17, 2018, to highlight the partnership and discuss current and future directions for its research activities.
Source: EurekAlert! - Medicine and Health - September 17, 2018 Category: International Medicine & Public Health Source Type: news

There's an allergy epidemic in Africa, and not enough specialists to deal with it
(Elsevier) Allergies are on the rise in Africa, but with too few specialists to treat them, and a parallel increase in immune deficiency diseases, the situation is worse than we thought. According to researchers from Ain Shams University in Egypt in an article in The Journal of Allergy and Clinical Immunology, the answer is more funding, motivated governments and better scientific partnerships.
Source: EurekAlert! - Medicine and Health - April 4, 2018 Category: International Medicine & Public Health Source Type: news

Study of Ebola survivors opens in Liberia
(NIH/National Institute of Allergy and Infectious Diseases) The Liberia-US clinical research partnership known as PREVAIL has launched a study of people in Liberia who have survived Ebola virus disease (EVD) within the past two years. The clinical trial investigators hope to better understand the long-term health consequences of EVD, determine if survivors develop immunity that will protect them from future Ebola infection, and assess whether previously EVD-infected individuals can transmit infection to close contacts and sexual partners.
Source: EurekAlert! - Medicine and Health - June 17, 2015 Category: Global & Universal Source Type: news

Ebola test vaccines appear safe in phase 2 Liberian clinical trial
(NIH/National Institute of Allergy and Infectious Diseases) Two experimental Ebola vaccines appear to be safe based on evaluation in more than 600 people in Liberia who participated in the first stage of the Partnership for Research on Ebola Vaccines in Liberia Phase 2/3 clinical trial, according to interim findings from an independent Data and Safety Monitoring Board review. Based on these findings, the study, which is sponsored by the NIAID, part of the National Institutes of Health, may now advance to Phase 3 testing.
Source: EurekAlert! - Medicine and Health - March 26, 2015 Category: Global & Universal Source Type: news

Liberia-US clinical research partnership opens trial to test Ebola treatments
(NIH/National Institute of Allergy and Infectious Diseases) In partnership with the Liberian government, the National Institute of Allergy and Infectious Diseases today launched a clinical trial to obtain safety and efficacy data on the investigational drug ZMapp as a treatment for Ebola virus disease. The study, which will be conducted in Liberia and the United States, is a randomized controlled trial enrolling adults and children with known Ebola virus infection.
Source: EurekAlert! - Medicine and Health - February 27, 2015 Category: Global & Universal Source Type: news

NIH grants license agreement for candidate Ebola vaccines
(NIH/National Institute of Allergy and Infectious Diseases) NIAID today announced a new license agreement aimed at advancing dual-purpose candidate vaccines to protect against rabies and Ebola viruses. The vaccines were created by scientists at NIAID and Thomas Jefferson University in Philadelphia and are being further developed through a partnership with the German pharmaceutical company IDT Biologika. The candidate vaccines now have been licensed to Exxell BIO of Saint Paul, Minnesota, which aims to advance the products through clinical testing and commercialization.
Source: EurekAlert! - Medicine and Health - October 15, 2014 Category: Global & Universal Source Type: news